Related Experiment Video
Updated: May 24, 2025
Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
Published on: April 19, 2024
[Comparing the efficacy of divozilimab and second-line treatments for relapsing-remitting multiple sclerosis in the
M N Zakharova1, T O Simaniv1, K V Sapozhnikov2
1Research Center of Neurology, Moscow, Russia.
Objective:
To compare efficacy of the new drug divozilimab with other second-line treatment options for relapsing remitting multiple sclerosis (RRMS) that have been already included or submitted application to be included into the «14 high-cost nosologies» program in the Russian Federation.
Material And Methods:
We conducted systematic literature review (PROSPERO ID CRD42022310082) and frequentist network meta-analysis of 2-years efficacy of divozilimab and other second-line therapies to treat RRMS.
Results:
Annualized relapse rate ratio in divozilimab vs fingolimod was 0.4 (95% CI 0.3-0.7), divozilimab vs cladribin 0.5 (95% CI 0.3-0.9), divozilimab vs alemtuzumab 0.7 (95% CI 0.3-1.7), divozilimab vs ocrelizumab 0.7 (95% CI 0.3-1.6), divozilimab vs ofatumumab 0.7 (95% CI 0.4-1.1), divozilimab vs natalizumab 0.4 (95% CI 0.4-1.1) respectively. Divozilimab had the highest SUCRA rank (0.9) while fingolimod had the lowest (0.4).
Conclusion:
Systematic literature review and network meta-analysis revealed statistically significant superiority of divozilimab over cladribine and fingolimod and absence of statistically significant differences with alemtuzumab, ocrelizumab, ofatumumab and natalizumab in the annual relapse rate during 2 years of treatment.
More Related Videos
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
